Tempus AI (NASDAQ:TEM) Issues Earnings Results

Tempus AI (NASDAQ:TEM) issued its quarterly earnings results on Tuesday. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01, FiscalAI reports. The business had revenue of $367.21 million for the quarter, compared to analyst estimates of $362.55 million. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.

Tempus AI Stock Performance

Tempus AI stock traded up $0.66 during mid-day trading on Tuesday, hitting $57.95. The company had a trading volume of 5,258,551 shares, compared to its average volume of 5,680,159. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45. The company has a market capitalization of $10.31 billion, a price-to-earnings ratio of -48.70 and a beta of 5.22. The company’s fifty day moving average is $62.13 and its 200-day moving average is $73.61. Tempus AI has a 12-month low of $36.22 and a 12-month high of $104.32.

More Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Launched HRD‑RNA and added lung‑cancer screening via a Median Technologies partnership — broadens Tempus’s clinical offerings for treatment selection and early detection, supporting future revenue diversification and cross‑sell into oncology workflows. Tempus AI Expands Cancer Workflow With HRD-RNA Launch And Lung Screening
• Positive Sentiment: Imaging push gains traction — analysts note the Median deal and prior FDA clearances strengthen Tempus’s move into radiology/AI imaging, which could increase Pixel platform adoption and create new revenue streams. Here’s How Tempus AI Is Tapping the Imagining Space
• Neutral Sentiment: Earnings preview — analysts and previews flag key items investors will watch in the print: revenue growth, margin progress, guidance, and product monetization (testing, Pixel imaging uptake). The report sets expectations that could drive post‑report volatility. What’s Next: Tempus AI’s Earnings Preview
• Neutral Sentiment: Live earnings coverage in play — real‑time updates and market reaction are being tracked; results or guidance surprises are the most likely immediate drivers of today’s price action. Live Earnings: Will Tempus AI Surprise Wall Street Tonight?
• Negative Sentiment: Significant insider selling reported — multiple senior executives (CEO, CFO, and EVPs) sold shares on 2/23, totaling roughly $2.9M of disclosed sales; large, clustered insider sales can raise investor concern about insider confidence or signal personal liquidity moves. Tempus AI (NASDAQ:TEM) CEO Sells $566,407.60 in Stock Tempus AI (NASDAQ:TEM) CFO Sells $595,460.20 in Stock Tempus AI (NASDAQ:TEM) EVP Sells $660,334.19 in Stock

Insider Activity

In related news, EVP Erik Phelps sold 9,464 shares of the firm’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $59.43, for a total transaction of $562,445.52. Following the sale, the executive vice president owned 79,816 shares in the company, valued at approximately $4,743,464.88. This trade represents a 10.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Ryan Fukushima sold 9,592 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $59.05, for a total transaction of $566,407.60. Following the sale, the chief executive officer directly owned 694,354 shares in the company, valued at approximately $41,001,603.70. The trade was a 1.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 596,035 shares of company stock valued at $37,505,125 in the last three months. Corporate insiders own 26.27% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Voloridge Investment Management LLC increased its stake in Tempus AI by 183.0% during the 3rd quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock worth $129,708,000 after buying an additional 1,039,176 shares in the last quarter. AQR Capital Management LLC purchased a new stake in shares of Tempus AI during the second quarter worth approximately $54,020,000. Marshall Wace LLP raised its stake in Tempus AI by 1,109.1% in the 4th quarter. Marshall Wace LLP now owns 738,646 shares of the company’s stock valued at $43,617,000 after purchasing an additional 677,557 shares during the last quarter. Wellington Management Group LLP acquired a new position in Tempus AI in the 4th quarter valued at $25,550,000. Finally, ARK Investment Management LLC lifted its holdings in Tempus AI by 5.3% in the 4th quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock valued at $446,275,000 after purchasing an additional 381,816 shares in the last quarter. 24.22% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on TEM. Needham & Company LLC lifted their price objective on shares of Tempus AI from $70.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Piper Sandler dropped their price target on Tempus AI from $105.00 to $80.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 11th. Morgan Stanley raised their price objective on Tempus AI from $80.00 to $85.00 and gave the stock an “overweight” rating in a research note on Monday, December 1st. JPMorgan Chase & Co. dropped their target price on Tempus AI from $85.00 to $80.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. Finally, HC Wainwright reduced their price target on shares of Tempus AI from $98.00 to $89.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Eight research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $85.92.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.